NEW YORK, NY / ACCESS Newswire / April 21, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want ...

NEW YORK, NY / ACCESS Newswire / April 20, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want ...

Sandesh Seth, Chairman and CEO at Actium Pharmaceuticals, Inc. commented: "We believe that targeted radiation therapy with Actinium-225 is one of the most promising approaches for treating ...

Modern medicine is experiencing a period of significant advancements and innovations, and at its core is radiopharmaceuticals ...

Actinium has outlined its expanded market opportunities and expected 2025 milestones for each of its clinical programs as well as its R&D and radiopharmaceutical manufacturing capabilities as ...

StockNews.com upgraded shares of Actinium Pharmaceuticals (NYSE:ATNM – Free Report) from a sell rating to a hold rating in a ...

NEW YORK - Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM), a developer of targeted radiotherapies, announced the introduction of ATNM-400, a new radiotherapy for prostate cancer, and ...

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) between October 31, 2022 and August 2, 2024 ...

Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Actinium To Contact Him Directly To Discuss Their Options ...

NEW YORK, March 26, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, announced it will ...